Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is approximately 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The present opinion among 11 TipRanks analysts is for a moderate Buy rating of shares in CVS Health, with an average price target of eighty four dolars.

The analysts priced targets range from a high of $101 to a low of sixty one dolars.

From its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The retail or Long Term Care segment includes selling of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products and similar services, which includes medical, pharmacy, dental, behavioural health, healthcare control abilities. The Corporate segment involves in providing administrative services and management. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.